Scientific Advisory Board

Dr. Afdhal is Professor of Medicine at Harvard Medical School and Director of Hepatology and the Liver Center at Beth Israel Deaconess Medical Center, MA. An internationally recognized hepatologist, Dr. Afdhal’s clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension and has been clinical investigator on several trials. Dr. Afdhal serves as Chair of Clinical Advisory Board and is a Member of Scientific Advisory Boards at Spring Bank Pharmaceuticals, Inc. and Ligand Pharmaceuticals Inc. Dr. Afdhal has also been a Member of Strategic Advisory Board at Medgenics, Inc. since January 24, 2012. Dr. Afdhal is on the advisory board of the American Liver Foundation and the Massachusetts State Advisory Board for HCV. He has published more than 180 papers in journals such as Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and two books.
Dr. Cooper is Professor of Surgery, Director of Kidney and Pancreas Transplantation, Medstar Georgetown Transplant Institute, at Georgetown University Medical Center in Washington, D.C. As director of MedStar Georgetown’s Kidney Transplant Program, Dr. Cooper’s focus is living donation and living donor safety. Dr. Cooper also serves on the board of the United Network for Organ Sharing (UNOS). He was immediate past chair of the Living Donor Committee as well as the National Kidney Foundation. Dr. Cooper is also a member of the National Kidney Foundation's public policy committee, living donor council executive committee and "End the Wait" task force.
Dr. Elias is the Frank L. Day Professor of Biology and Dean of Medicine and Biologic Sciences at Brown University. With a professional career spanning over 30 years, he has made seminal contributions to our understanding of interstitial lung disease. Previously Chair of Medicine at Yale University, Dr. Elias, whose recent honors include election to the Institute of Medicine and the presidency of the Association of American Physicians, has published over 200 original peer-reviewed research papers and has frequently earned funding from industry and private foundations.
Dr. Fogo is the John L. Shapiro Chair of Pathology, Professor of Pathology, Medicine and Pediatrics and Director, Division of Renal Pathology and Electron Microscopy at Vanderbilt University Medical Center. An expert in the area of glomerulosclerosis, Dr. Fogo has published over 280 research articles and reviews and has authored two textbooks of renal pathology. She has served as Pathology Editor for the American Journal of Kidney Disease, Associate Editor for American Journal of Pathology and The Journal of the American Society of Nephrology. She is currently Section Editor for Nephrology Dialysis and Transplantation and Associate Editor for Laboratory Investigation.
Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Mount Sinai School of Medicine. Having performed pioneering research into the underlying causes of hepatic fibrosis, he is considered an opinion leader in liver diseases. Dr. Friedman is also broadly recognized as a respected clinician, educator, scientist and academic leader. The 2003 International Hans Popper Awardee, Dr. Friedman is a past President of the American Association for the Study of Liver Diseases.
Dr. Guengerich is the Tadashi Inagami Chair in Biochemistry, Professor of Biochemistry and Director of the Center in Molecular Toxicology at Vanderbilt University. He is author or co-author of over 500 peer-reviewed scientific articles, and brings considerable expertise in toxicology, investigating cytochrome P450, DNA damage and carcinogenesis, and drug metabolism. Dr. Guengerich’s group has published three papers in the Journal of Biological Chemistry that have had a major impact on the pharmaceutical industry and the field of biochemical research.
Matthew R. Weir, MD, is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School Of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, blood pressure salt sensitivity, biomeasures of cardiovascular disease, and preventing allograft nephropathy in transplant recipients. He has written more than 500 manuscripts and book chapters about these topics.